Ziegler Capital Management’s AnaptysBio ANAB Stock Holding History

Ziegler Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-23,262	Closed	-$593K	–	396
2022 Q3	$593K	Sell	23,262 -136	-0.6%	-$3.19K	0.03%	335
2022 Q2	$475K	Buy	23,398 +624	+3%	+$13.8K	0.02%	350
2022 Q1	$563K	Sell	22,774 -2,400	-10%	-$72.6K	0.02%	331
2021 Q4	$875K	Sell	25,174 -8,031	-24%	-$255K	0.03%	335
2021 Q3	$901K	Buy	+33,205	New	+$843K	0.03%	341

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Ziegler Capital Management's ANAB Position: Q4 2022 in Review

Ziegler Capital Management sold out of AnaptysBio (ANAB) in Q4 2022, closing a stake of 23,262 shares — an estimated $593K sold.

Ziegler Capital Management first reported a position in ANAB in Q3 2021 and held it in 5 quarters. The position peaked at $901K in Q3 2021. 118 funds tracked by Wall St. Rank hold ANAB as of Q4 2022.

Ziegler Capital Management reported no remaining AnaptysBio position as of Q4 2022 after selling out during the quarter.
Ziegler Capital Management sold 23,262 AnaptysBio shares in Q4 2022, an estimated $593K.
Ziegler Capital Management first reported a position in AnaptysBio in Q3 2021 and held it in 5 quarters.
Ziegler Capital Management's AnaptysBio position peaked at $901K in Q3 2021.
118 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2022.

Based on Ziegler Capital Management's 13F filing for Q4 2022, filed 24 Jan 2023.